ZURICH--(BUSINESS WIRE)--Regulatory News:
19 April 2023: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to provide updates on production and sales.
The Company continues to obtain intermittent results confirming the performance of the product and customer acceptance, however it continues to struggle to connect production to sales in Indonesia. Whilst production and supply out of Taiwan, Spain, Singapore, and parts of Indonesia are of a commercial grade, last mile issues in Indonesia continue to be a challenge. The Company has been working to reorganise production and distribution arrangements in Indonesia and look to other markets.
“With the time that this has taken and some unusual behaviour by some former staff, the Company has reached a point where its solvency and regulatory obligations are challenged”, said Steven Goh, CEO of Achiko AG. “The Board is actively working towards a solution and hopes to be able to present this to shareholders in the near future.”
ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport. AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.
Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.